PET-CT

Prognostic and Differential Diagnostic Value of Standardized Uptake Volume (SUV) of Fluorodeoxyglucose in Patients with Hodgkin’s Lymphoma

LYMPHOID TUMORS , ,

AA Rukavitsyn, SI Kurbanov, OA Rukavitsyn

Academician NN Burdenko Principal Military Clinical Hospital under the Ministry of Defence of the Russian Federation, 3 Gospital’naya pl., Moscow, Russian Federation, 105229

For correspondence: Anatolii Anatol’evich Rukavitsyn, 3 Gospital’naya pl., Moscow, Russian Federation, 105229; Tel: +7(499)263-53-17; e-mail: rukavitsin46@gmail.com

For citation: Rukavitsyn AA, Kurbanov SI, Rukavitsyn OA. Prognostic and Differential Diagnostic Value of Standardized Uptake Volume (SUV) of Fluorodeoxyglucose in Patients with Hodgkin’s Lymphoma. Clinical oncohematology. 2017;10(2):182–6 (In Russ).

DOI: 10.21320/2500-2139-2017-10-2-182-186

ABSTRACT

Background & Aims. Hodgkin’s lymphoma (HL) is still considered one of the most curable oncohematological diseases of lymphoid tissue. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) combined with multispiral computed tomography (CT) is one of precise and easily available methods of imaging of lymphoid neoplasia. The aim is to determine the correlation between the standardized uptake volume (SUV) of 18F-FDG and results of the first-line anti-tumor treatment of HL patients; to evaluate the possibility of differential diagnosis between HL and diffuse large B-cell lymphomas (DLBCL) based on SUV.

Materials & Methods. 76 patients (69 men and 7 women) aged from 19 to 75 years (median age 36.7 years) with DLBCL (n = 22) and HL (n = 54) were retrospectively enrolled in the study. The diseases were diagnosed over the period from 2011 until 2015. A combined PET-CT imaging was performed for the disease staging.

Results. The comparison of median SUVs in patients with HL (n = 54) and DLBCL (n = 22) demonstrated that the difference had a very high level of significance (p < 0.001). HL patients demonstrated a significantly lower 18F-FDG SUV than DLBCL patients. The analysis of PET findings demonstrated a correlation between the chosen treatment option for the lymphoma and the SUV level (p < 0.001). HL patients demonstrated an insignificant negative correlation between the SUV level rise and the treatment outcome (p = 0.2).

Conclusion. The SUV level does not affect the treatment outcomes of HL patients according to the ABVD protocol, as well as the metabolic response rate and tumor mass reduction. However, the SUV levels significantly differ in patients with HL and DLBCL. These data may be used as additional criteria for differential diagnosis of HL and DLBCL.

Keywords: SUV, PET-CT, Hodgkin’s lymphoma, DLBCL.

Received: November 21, 2016

Accepted: January 23, 2017

Read in PDF (RUS)pdficon

REFERENCES

  1. Гематология: национальное руководство. Под ред. О.А. Рукавицына. М.: ГЭОТАР-Медиа, 2015. 776 с.
    [Rukavitsyn OA, ed. Gematologiya: natsional’noe rukovodstvo. (Hematology: national guidelines.) Moscow: GEOTAR-Media Publ.; 2015. 776 p. (In Russ)]
  2. Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32. doi: 10.1182/blood-2011-01-293050.
  3. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32(27):3059–67. doi: 10.1200/jco.2013.54.8800.
  4. Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer. 2004;90(3):620–5. doi: 10.1038/sj.bjc.6601561.
  5. D’souza MM, Jaimini A, Bansal A, et al. FDG-PET/CT in lymphoma. Indian J Radiol Imaging. 2013;23(4):354–65. doi: 10.4103/0971-3026.125626.
  6. Ngeow JYY, Quek RHH, Ng DCE, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol. 2009;20(9):1543–7. doi: 10.1093/annonc/mdp030.
  7. Schoder H, Noy A, Gonen M, et al. Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma. J Clin Oncol. 2005;23(21):4643–51. doi: 10.1200/jco.2005.12.072.

 

 

Features of Imaging of Different Types of Hodgkin’s Lymphoma Using Combined Positron Emission and Computed Tomography

LYMPHOID TUMORS , , ,

AS Subbotin1, NG Afanas’eva2

1 Chelyabinsk District Clinical Oncological Dispensary, 42 Blyukhera str., Chelyabinsk, Russian Federation, 454087

2 South Ural State Medical University, 64 Vorovskogo str., Chelyabinsk, Russian Federation, 454092

For correspondence: Aleksei Sergeevich Subbotin, 42 Blyukhera str., Chelyabinsk, Russian Federation, 454087; e-mail: acsubbotin@yandex.ru

For citation: Subbotin AS, Afanas’eva NG. Features of Imaging of Different Types of Hodgkin’s Lymphoma Using Combined Positron Emission and Computed Tomography. Clinical oncohematology. 2017;10(1):61–4(In Russ).

DOI: 10.21320/2500-2139-2017-10-1-61-64

ABSTRACT

Background & Aims. At present, PET-CT has an important clinical significance in Hodgkin’s lymphoma (HL) and is used both for initial tumor staging and restaging and for the evaluation of treatment efficacy. Published data indicate the possible lack of radiotracer accumulation in the tumor tissue in HL before primary treatment. A low metabolic activity of the tumor tissue prior to treatment makes it difficult to assess the treatment dynamics during the anti-tumor therapy. The aim of this work is to determine the incidence of the low metabolic activity of tumor tissue in HL.

Methods. Findings of 131 18F-fluorodeoxyglucose (FDG) whole body PET-CT scans of patients with histologically verified HL (over the period from 2011 to 2015) were studied retrospectively. Patterns of FDG accumulation in different histological types of HL, as well as the levels of metabolic activity in patients with tumor-related toxicity symptoms (B-symptoms) were studied.

Results. The low metabolic activity was detected in 4 % of patients with de novo HL. The highest levels of metabolic activity were detected in nodular sclerosis and the lowest ones in nodular lymphocyte-predominant HL. Higher levels of radiotracer metabolic activity were observed in patients with general symptoms.

Conclusion. In general, a high metabolic activity of the neoplasm is typical for HL. Primary staging before the treatment should be performed for a more accurate evaluation of dynamics of HL treatment outcomes, because in a number of cases a baseline low FDG accumulation in the neoplasm may imitate the absence of a viable tumor tissue in the affected lymph nodes at assessment of treatment results.

Keywords: Hodgkin’s lymphoma, histological types, PET-CT, 18F-fluorodeoxyglucose.

Received: August 25, 2016

Accepted: December 19, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Ильин Н.В., Виноградова Ю.Н. Отдаленные последствия лучевой и комбинированной терапии больных лимфомой Ходжкина. Клиническая онкогематология. 2008;1(2):131–5.
    [Ilyin NV, Vinogradova YuN. Late side effects after radio- and combined therapy in patients with Hodgkin’s lymphoma. Klinicheskaya onkogematologiya. 2008;1(2):131–5. (In Russ)]
  2. Курпешев О.К., Павлов В.В., Шкляев С.С. Эффективность локальной гипертермии при химиотерапевтическом и/или лучевом лечении рецидивов лимфомы Ходжкина. Сибирский онкологический журнал. 2013;4(58):28–30.
    [Kupreshev OK, Pavlov VV, Shklyaev SS. Efficacy of local hyperthermia in chemotherapy and/or radiation therapy for recurrences of Hodgkin’s lymphoma. Sibirskii onkologicheskii zhurnal. 2013;4(58):28–30. (In Russ)]
  3. Гранов А.М., Ильин Н.В. (ред.) Лимфомы. СПб.: РНЦРХТ, 2010. С. 222–40.
    [Granov AM, Il’in NV, eds. Limphomy. (Lymphomas.) Saint Petersburg: RNCRHT Publ.; 2010. pp. 222–40. (In Russ)]
  4. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54(5):683–90. doi: 10.2967/jnumed.112.110890.
  5. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58. doi: 10.1200/jco.2013.53.5229.
  6. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. doi: 10.1200/jco.2013.54.8800.
  7. Труфанов Г.Е., Рязанов В.В., Дергунова Н.И. и др. Совмещенная позитронно-эмиссионная и компьютерная томография (ПЭТ-КТ) в онкологии. СПб.: ЭЛБИ-СПб, 2005. 124 c.
    [Trufanov GE, Ryazanov VV, Dergunova NI, et al. Sovmeschennaya pozitronno-emissionnaya i kompyuternaya tomographiya (PET-KT) v onkologii. (Combined positron emission and computed tomography (PET-CT) in oncology.) Saint-Petersburg: ELBI-SPb.; 2005. 124 p. (In Russ)]
  8. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients. J Nucl Med. 2010;51(1):25–30. doi: 10.2967/jnumed.109.067892.
  9. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110(3):652–9. doi: 10.1002/cncr.22807.
  10. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101(10):3875–6. doi: 10.1182/blood-2002-09-2778.